	US 12,419,832 B2
	Intratumoral delivery of bortezomib
Thomas Chen, La Canada (CA); and Yehoshua Shachar, Santa Monica, CA (US)
Assigned to COGNOS THERAPEUTICS, INC., Los Angeles, CA (US)
Appl. No. 16/965,051
Filed by Cognos Therapeutics, Inc., Los Angeles, CA (US)
PCT Filed Jan. 29, 2019, PCT No. PCT/US2019/015634 § 371(c)(1), (2) Date Jul. 27, 2020, PCT Pub. No. WO2019/148181, PCT Pub. Date Aug. 1, 2019.
Claims priority of provisional application 62/623,100, filed on Jan. 29, 2018.
Prior Publication US 2021/0106522 A1, Apr. 15, 2021
Int. Cl. A61K 9/00 (2006.01); A61K 31/69 (2006.01); A61K 45/06 (2006.01); A61M 5/142 (2006.01); A61P 35/04 (2006.01)

CPC A61K 9/0085 (2013.01) [A61K 31/69 (2013.01); A61M 5/14276 (2013.01); A61P 35/04 (2018.01); A61K 45/06 (2013.01)]

4 Claims

1. A method of administering bortezomib comprising delivering bortezomib into a brain tumor by a pump implanted in a brain of a subject, wherein the pump consists of a therapeutically effective amount of bortezomib.